Transarterial chemoembolization (TACE) improves survival in cirrhotic patients with hepatocellular carcinoma (HCC). The optimal schedule, best anticancer agent and best technique are still unclear.

Hepatocellular carcinoma (HCC) is the fourth leading cause of cancer-related death worldwide. Multiple treatment modalities ...

LIVER cancer is the fourth most common cancer in Malaysia and also the fourth leading cause of cancer-related deaths.

The Food and Drug Administration (FDA) has approved Opdivo ® (nivolumab) in combination with Yervoy ® (ipilimumab) for the first-line treatment of adult patients with unresectable or metastatic ...

Hepatocellular carcinoma is the most common form of liver cancer. Patients whose cancer cannot be removed by surgery are ...

The combination therapy can be used as first-line treatment for unresectable or metastatic forms of the cancer.

Researchers sought to test the performance of a deep learning model system using longitudinal magnetic resonance imaging (MRI) in predicting early recurrence in patients with hepatocellular carcinoma.

Japanese researchers sought to build upon prior studies demonstrating the feasibility of liver resection in geriatric hepatocellular carcinoma patients, particularly in those undergoing major ...

Transarterial chemoembolization (TACE) is currently the most common approach for the management of hepatocellular carcinoma (HCC) without curative options. TACE consists of the injection of ...